At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Use Surveillance for Cabometyx Tablets "Renal Cell Carcinoma"
In Brief
An observational study evaluating Cabozantinib for Renal Cell Carcinoma. Completed, enrolled 388 participants across 1 site.
Detailed Summary
This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with renal cell carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 26 weeks.
Study Details
Timeline
Interventions
Cabozantinib tablets